Format

Send to

Choose Destination
Trends Neurosci. 2014 Nov;37(11):629-41. doi: 10.1016/j.tins.2014.07.002. Epub 2014 Aug 20.

MicroPET imaging and transgenic models: a blueprint for Alzheimer's disease clinical research.

Author information

1
Translational Neuroimaging Laboratory (TNL), McGill Center for Studies in Aging, Douglas Mental Health University Institute, Montreal, Quebec, Canada; PET unit, Montreal Neurological Institute (MNI), Montreal, Quebec, Canada; Department of Biochemistry, Federal University of Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
2
Translational Neuroimaging Laboratory (TNL), McGill Center for Studies in Aging, Douglas Mental Health University Institute, Montreal, Quebec, Canada; PET unit, Montreal Neurological Institute (MNI), Montreal, Quebec, Canada.
3
Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada.
4
Translational Neuroimaging Laboratory (TNL), McGill Center for Studies in Aging, Douglas Mental Health University Institute, Montreal, Quebec, Canada; PET unit, Montreal Neurological Institute (MNI), Montreal, Quebec, Canada. Electronic address: pedro.rosa@mcgill.ca.

Abstract

Over the past decades, developments in neuroimaging have significantly contributed to the understanding of Alzheimer's disease (AD) pathophysiology. Specifically, positron emission tomography (PET) imaging agents targeting amyloid deposition have provided unprecedented opportunities for refining in vivo diagnosis, monitoring disease propagation, and advancing AD clinical trials. Furthermore, the use of a miniaturized version of PET (microPET) in transgenic (Tg) animals has been a successful strategy for accelerating the development of novel radiopharmaceuticals. However, advanced applications of microPET focusing on the longitudinal propagation of AD pathophysiology or therapeutic strategies remain in their infancy. This review highlights what we have learned from microPET imaging in Tg models displaying amyloid and tau pathology, and anticipates cutting-edge applications with high translational value to clinical research.

KEYWORDS:

Alzheimer's disease; amyloid; microPET; neurodegeneration; positron emission tomography; radiopharmaceuticals

PMID:
25151336
DOI:
10.1016/j.tins.2014.07.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center